Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement (HEAL-LAST)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06052176 |
Recruitment Status :
Recruiting
First Posted : September 25, 2023
Last Update Posted : January 3, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Hypothesis: Improvement in cognitive dysfunction with IV albumin in patients with cirrhosis with prior HE and MHE lasts for several weeks after albumin infusion has ended, and is due to persistent improvement in inflammatory markers, endothelial dysfunction, albumin function and gut microbial changes.
This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cirrhosis Hepatic Encephalopathy | Drug: Albumin Infusion | Phase 2 |
In outpatients with cirrhosis with prior HE who have cognitive impairment despite adequate therapy, how long the impact of albumin lasts and through which potential mechanism(s) needs to be determined.
A prior recent HEAL trial showed that patients with prior HE and current minimal hepatic encephalopathy (MHE) randomized to albumin experienced significant improvement in cognitive dysfunction and psychosocial quality of life. Moreover, these improvements persisted a week after the last albumin infusion, which was not seen in the placebo group. This was accompanied by an improvement in endothelial dysfunction, ischemia-modified albumin levels and inflammatory markers that persisted one week even after albumin discontinuation. The reported half-life of IV albumin is 2 weeks, but the function and the length of time of albumin's action in decompensated cirrhosis is lower, and further details surrounding albumin pharmacokinetics in this population remain unelucidated. The mechanisms and length of time albumin's potential improvement for patients with MHE after treatment discontinuation also require continued study.
Study design:
This will be a single-arm, single-blind sequential trial of IV 25% albumin and IV saline over 8 weeks with biological sampling and cognitive and health related quality of life (HRQOL) testing with each subject acting as their own control.
Th order of the albumin and placebo infusion and blind the infusions from the subjects and the assessors of the outcomes will be changed.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Masking Description: | Subjects will be blinded to which infusions are albumin versus placebo. All infusion tubing and bag will be covered in foil and the subjects will not be aware of the timing of the saline vs albumin infusion to maintain blinding for the patient. |
Primary Purpose: | Prevention |
Official Title: | Randomized Clinical Trial in Hepatic Encephalopathy to Study Lasting Cognitive Improvement With Intravenous Albumin |
Actual Study Start Date : | November 2, 2023 |
Estimated Primary Completion Date : | March 1, 2025 |
Estimated Study Completion Date : | June 1, 2025 |
Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Saline given at the same volume as the albumin on visits the patients are assigned to it
|
Drug: Albumin Infusion
Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
Other Name: Albutein |
Active Comparator: Albumin
IV Albumin at 1.5g/kg ideal body weight
|
Drug: Albumin Infusion
Intravenous human serum albumin to be given at 1.5g/kg ideal body weight
Other Name: Albutein |
- Delta change in Psychometric Hepatic Encephalopathy Score (PHES) in Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]cognitive improvement (PHES score ranges from -15 to 5), higher is good
- EncephalApp Stroop change in Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]cognitive improvement (Stroop OffTime+OnTime in seconds will be evaluated); higher is worse
- Critical Flicker Frequency change in Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]cognitive improvement (Hz at which CFF is reached will be evaluated), higher is good
- Change in Sickness Impact Profile Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Health-related quality of life change (SIP total, psychosocial and physical scores where a higher score indicates poor HRQOL willl be evaluated)
- Change in PROMIS-29 Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Health-related quality of life change (Total PROMIS-29 score will be evaluated)
- Change in MELD-Na score Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Liver disease severity change using MELD-Na; higher is worse
- Change in endotoxin binding protein Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in endotoxin binding protein will be recorded in the serum; higher is worse
- Change in oxidized albumin Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in oxidized albumin will be recorded in the serum ; higher is worse
- Change in ischemia modified albumin Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in ischemia modified albumin will be recorded in the serum
- Change in stool bile acids Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in stool bile acids (total, primary, secondary, conjugated/deconjugated) will be recorded
- Change in serum bile acids Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in serum bile acids (total, primary, secondary, conjugated/deconjugated) will be recorded
- Change in serum Short-chain fatty acids Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in serum Short-chain fatty acids (acetate, propionate, butyrate will be recorded
- Change in stool Short-chain fatty acids Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in stool Short-chain fatty acids (acetate, propionate, butyrate will be recorded
- Change in stool bacterial alpha diversity Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in Shannon diversity of stool bacteria
- Change in serum inflammatory cytokines Placebo phase vs Albumin phase [ Time Frame: 4 weeks each ]Change in IL-6, TNF-α, IL-10, IL-1β in serum
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age >18 years
- Cirrhosis diagnosed using either (a) liver biopsy, (b) transient wave elastography (>20 KPa) (c) radiological evidence consistent with cirrhosis, (d) in a patient with chronic liver disease endoscopic or radiological evidence of varices (e), in a patient with chronic liver disease, platelet count <150,000/mm3 and AST/ALT ratio >1.
- Cognitive impairment defined by MHE on psychometric hepatic encephalopathy score (PHES), critical flicker frequency (CFF), or EncephalApp Stroop
- Prior HE controlled by lactulose or rifaximin for at least one month
- Serum albumin <4gm/dl
Exclusion Criteria:
- Unclear diagnosis of cirrhosis
- No prior overt HE
- No cognitive impairment on the tests noted
- Requiring regular albumin infusions within 3 months or anticipated during the study visit
- Infection within a month
- Allergies to albumin
- Unlikely to be adherent to the study
- Unable or unwilling to consent
- West Haven Criteria>2
- Alcohol abuse within 1 month
- Serum albumin >4gm/dl
- Congestive heart failure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06052176
Contact: Jasmohan Bajaj, MD | 8046755802 | jasmohan.bajaj@vcuhealth.org |
United States, Virginia | |
Hunter Holmes McGuire VA Medical Center | Recruiting |
Richmond, Virginia, United States, 23249 | |
Contact: Haley Obolewicz, RN 804-675-5000 ext 6733 haley.obolewicz@va.gov | |
Contact: Travis Mousel, RN 804 675 5584 travis.mousel@va.gov | |
Principal Investigator: Jasmohan S Bajaj, MD, MSc |
Responsible Party: | Hunter Holmes Mcguire Veteran Affairs Medical Center |
ClinicalTrials.gov Identifier: | NCT06052176 |
Other Study ID Numbers: |
BAJAJ0035 |
First Posted: | September 25, 2023 Key Record Dates |
Last Update Posted: | January 3, 2024 |
Last Verified: | December 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
albumin cirrhosis inflammation cognitive performance |
Hepatic Encephalopathy Brain Diseases Fibrosis Pathologic Processes Liver Diseases Digestive System Diseases |
Central Nervous System Diseases Nervous System Diseases Liver Failure Hepatic Insufficiency Brain Diseases, Metabolic Metabolic Diseases |